Galapagos Nv (GLPG)

$28.62

-0.15

(-0.52%)▲

Live

Insights on Galapagos Nv

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 178.86M → -209.12M (in $), with an average decrease of 103.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, 5.10M → 157.55M (in $), with an average increase of 81.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 74.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 305.4%

Performance

  • $28.35
    $28.74
    $28.62
    downward going graph

    0.94%

    Downside

    Day's Volatility :1.36%

    Upside

    0.42%

    downward going graph
  • $28.62
    $45.21
    $28.62
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :36.7%

    Upside

    36.7%

    downward going graph

Returns

PeriodGalapagos NvSector (Health Care)Index (Russel 2000)
3 Months
-23.3%
1.7%
0.0%
6 Months
-12.15%
11.3%
0.0%
1 Year
-25.02%
5.4%
1.3%
3 Years
-65.48%
13.9%
-22.1%

Highlights

Market Capitalization
1.9B
Book Value
$42.42
Earnings Per Share (EPS)
-0.06
PEG Ratio
0.0
Wall Street Target Price
41.84
Profit Margin
88.31%
Operating Margin TTM
-33.63%
Return On Assets TTM
-1.11%
Return On Equity TTM
-0.15%
Revenue TTM
239.7M
Revenue Per Share TTM
0.18
Quarterly Revenue Growth YOY
-11.899999999999999%
Gross Profit TTM
4.8M
EBITDA
-57.3M
Diluted Eps TTM
-0.06
Quarterly Earnings Growth YOY
0.19
EPS Estimate Current Year
-1.05
EPS Estimate Next Year
-1.28
EPS Estimate Current Quarter
-1.27
EPS Estimate Next Quarter
-1.01

Analyst Recommendation

Hold
    36%Buy
    63%Hold
    0
    0%Sell
Based on 19 Wall street analysts offering stock ratings for Galapagos Nv(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
12
12
10
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 46.19%

Current $28.62
Target $41.84

Company Financials

FY18Y/Y Change
Revenue
330.4M
↑ 127.27%
Net Income
-33.5M
↓ 74.71%
Net Profit Margin
-10.13%
↑ 80.91%
FY19Y/Y Change
Revenue
946.6M
↑ 192.55%
Net Income
167.9M
↓ 612.13%
Net Profit Margin
17.73%
↑ 27.86%
FY20Y/Y Change
Revenue
588.0M
↓ 43.42%
Net Income
-382.5M
↓ 307.55%
Net Profit Margin
-65.06%
↓ 82.79%
FY21Y/Y Change
Revenue
549.1M
↑ 1.42%
Net Income
-142.0M
↓ 59.67%
Net Profit Margin
-25.87%
↑ 39.19%
FY22Y/Y Change
Revenue
541.3M
↑ 4.21%
Net Income
-233.5M
↑ 73.81%
Net Profit Margin
-43.14%
↓ 17.27%
FY23Y/Y Change
Revenue
239.7M
↓ 52.56%
Net Income
211.7M
↓ 197.11%
Net Profit Margin
88.31%
↑ 131.45%
Q3 FY22Q/Q Change
Revenue
133.9M
↓ 1.02%
Net Income
21.2M
↓ 213.28%
Net Profit Margin
15.82%
↑ 29.65%
Q4 FY22Q/Q Change
Revenue
101.9M
↓ 30.16%
Net Income
-222.0M
↓ 1061.34%
Net Profit Margin
-217.84%
↓ 233.66%
Q1 FY23Q/Q Change
Revenue
195.1M
↑ 88.04%
Net Income
25.3M
↓ 111.2%
Net Profit Margin
12.97%
↑ 230.81%
Q2 FY23Q/Q Change
Revenue
163.6M
↓ 16.17%
Net Income
5.6M
↓ 78.02%
Net Profit Margin
3.4%
↓ 9.57%
Q3 FY23Q/Q Change
Revenue
120.0M
↓ 19.96%
Net Income
25.8M
↑ 406.37%
Net Profit Margin
21.52%
↑ 18.12%
Q4 FY23Q/Q Change
Revenue
-209.1M
↓ 274.23%
Net Income
157.6M
↑ 509.98%
Net Profit Margin
-75.34%
↓ 96.86%
FY18Y/Y Change
Total Assets
1.6B
↑ 11.91%
Total Liabilities
257.7M
↓ 17.88%
FY19Y/Y Change
Total Assets
6.8B
↑ 321.58%
Total Liabilities
3.6B
↑ 1317.53%
FY20Y/Y Change
Total Assets
7.0B
↓ 5.78%
Total Liabilities
3.7B
↓ 4.56%
FY21Y/Y Change
Total Assets
5.9B
↓ 9.17%
Total Liabilities
2.9B
↓ 16.33%
FY22Y/Y Change
Total Assets
5.1B
↓ 8.83%
Total Liabilities
2.4B
↓ 13.39%
FY23Y/Y Change
Total Assets
4.4B
↓ 7.96%
Total Liabilities
1.6B
↓ 29.28%
Q3 FY22Q/Q Change
Total Assets
4.9B
↓ 1.35%
Total Liabilities
2.2B
↓ 4.66%
Q4 FY22Q/Q Change
Total Assets
5.1B
↓ 4.78%
Total Liabilities
2.4B
↓ 3.22%
Q1 FY23Q/Q Change
Total Assets
5.1B
↓ 2.16%
Total Liabilities
2.3B
↓ 6.37%
Q2 FY23Q/Q Change
Total Assets
4.9B
↓ 2.37%
Total Liabilities
2.1B
↓ 6.25%
Q3 FY23Q/Q Change
Total Assets
4.5B
↓ 1.57%
Total Liabilities
1.8B
↓ 5.6%
Q4 FY23Q/Q Change
Total Assets
4.4B
↓ 2.11%
Total Liabilities
1.6B
↓ 14.64%
FY18Y/Y Change
Operating Cash Flow
-163.0M
↓ 3.1%
Investing Cash Flow
-18.2M
↑ 2798.72%
Financing Cash Flow
329.3M
↓ 18.53%
FY19Y/Y Change
Operating Cash Flow
3.6B
↓ 2352.2%
Investing Cash Flow
-4.2B
↑ 23556.28%
Financing Cash Flow
1.5B
↑ 364.0%
FY20Y/Y Change
Operating Cash Flow
-525.6M
↓ 113.32%
Investing Cash Flow
931.5M
↓ 120.12%
Financing Cash Flow
27.1M
↓ 98.35%
FY21Y/Y Change
Operating Cash Flow
-570.6M
↑ 17.9%
Investing Cash Flow
613.0M
↓ 28.53%
Financing Cash Flow
-4.4M
↓ 117.59%
FY22Y/Y Change
Operating Cash Flow
-536.2M
↓ 0.65%
Investing Cash Flow
-1.3B
↓ 330.12%
Financing Cash Flow
-1.6M
↓ 61.64%
Q3 FY22Q/Q Change
Operating Cash Flow
-115.0M
↓ 17.51%
Investing Cash Flow
-179.5M
↑ 23.69%
Financing Cash Flow
779.5K
↓ 336.01%
Q4 FY22Q/Q Change
Operating Cash Flow
-192.7M
↑ 53.8%
Investing Cash Flow
19.4M
↓ 109.92%
Financing Cash Flow
-2.1M
↓ 341.99%
Q1 FY23Q/Q Change
Operating Cash Flow
-103.5M
↓ 47.26%
Investing Cash Flow
199.1M
↑ 907.88%
Financing Cash Flow
-207.2K
↓ 90.1%
Q2 FY23Q/Q Change
Operating Cash Flow
-136.8M
↑ 32.2%
Investing Cash Flow
199.2M
↑ 0.0%
Financing Cash Flow
-1.7M
↑ 716.32%
Q3 FY23Q/Q Change
Operating Cash Flow
-118.8M
↓ 5.26%
Investing Cash Flow
182.5M
↑ 0.0%
Financing Cash Flow
-2.1M
↑ 33.4%

Technicals Summary

Sell

Neutral

Buy

Galapagos Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Galapagos Nv
Galapagos Nv
-11.96%
-12.15%
-25.02%
-65.48%
-74.51%
Moderna, Inc.
Moderna, Inc.
-1.39%
41.81%
-19.31%
-38.71%
322.88%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.68%
13.74%
14.81%
80.88%
159.02%
Novo Nordisk A/s
Novo Nordisk A/s
-2.24%
29.49%
49.67%
240.51%
421.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.67%
10.39%
20.74%
84.71%
129.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Galapagos Nv
Galapagos Nv
420.44
NA
0.0
-1.05
0.0
-0.01
NA
42.42
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.77
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.13
26.13
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
48.36
48.36
2.4
3.34
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.17
29.17
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Galapagos Nv
Galapagos Nv
Hold
$1.9B
-74.51%
420.44
88.31%
Moderna, Inc.
Moderna, Inc.
Buy
$41.3B
322.88%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.6B
159.02%
26.13
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.9B
421.0%
48.36
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$104.7B
129.52%
29.17
36.68%

Institutional Holdings

  • EcoR1 Capital, LLC

    8.74%

  • FMR Inc

    6.42%

  • Bvf Inc

    2.91%

  • Segall Bryant & Hamill

    1.33%

  • Prosight Management, LP

    1.26%

  • PRIMECAP Management Company

    1.03%

Company Information

Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.

Organization
Galapagos Nv
Employees
1123
CEO
Dr. Paulus A. Stoffels M.D., Ph.D.
Industry
Health Technology

Discover More

FAQs